Amid rumors of a potential business combination with the Oncoclinic (Onco3)a ALLINANCE HEALTH (AALR3) announced on Monday (24) the acquisition of 100% of diagnostic operations by imaging and clinical analysis in the city of São Paulo da TreatmentDiagnostic Medicine Company.
In a relevant fact to the Securities Commission (CVM), the group informs that the agreement was signed through the acquisition of the healing actions, which belonged to the refuses.
Around 12:45, AALR3 shares fell 0.35%quoted at R $ 11.32. The papers walk to close February with a low of 4%. In the year, however, the gains reach 32.4%
In addition to increasing the capillarity of Alliance in the state capital, the acquisition also expands the offer of complex exams, such as magnetic resonance imaging and tomography, and marks the company’s debut in the state capital with women’s health services.
According to Alliance, the business must Increase the revenue by about R $ 80 million Gross company operational.
Payment of the acquisition will be divided into installments for 36 months. In addition, there will be an extra part (EARN-OUT), whose value will depend on the cure performance during this period. The final price was calculated considering the company without debt.
Read too
The closure of the purchase still depends on regulatory approvals and the endorsement of the Administrative Council for Economic Defense (Cade), as well as the corporate restructuring of the cure.
Does it come fusion out there? The dating between OncoClinicos (Onco3) and Alliance
Since the second half of last year, the market has been following the unfolding of rumors involving some health sector players – one of them is that Onco (Onco3) and Allça Saúde (AALR3) would be in negotiations for a possible merger, according to information from the information from the information from the information columnist Lauro Jardim, from the newspaper “O Globo”.
Oncoclinicas recently made a capital increase of $ 1.5 billion, led by Banco Master, which now has 20.17% of the company specializing in oncology.
The founder of the company, doctor Bruno Ferrari, has 8.51% of shares, while Goldman Sachs, through their investment funds, controls a slice of 37.31%.
On the other hand, the Alliance Saúde Laboratories (former Alliar) is controlled by funds linked to businessman Nelson Tanure. Conversations between the two companies are still in early stage, with no expected immediate developments.
Oncoclinicas, however, stated that “explores and evaluates opportunities that may result in strengthening their operations and value creation to their shareholders”, but has not yet signed any agreement with the companies.
